Announcements Trials
Browse Landscape

Phase

Phase 3 3Phase 2 2Phase NA 1Phase 4 1

Status

Unknown 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Lymphoid 1Genitourinary 1Gastrointestinal 1Endocrine 1

Conditions

Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Multiple Sclerosis, Relapsing-Remitting 1

Interventions

Cytarabine 34Cyclophosphamide 21Vincristine 20Methotrexate 18Dexamethasone 18Mercaptopurine 16Idarubicin 16nilotinib 15Daunorubicin 15Imatinib Mesylate 13fludarabine 12Granulocyte Colony-Stimulating Factor 12Asparaginase 12Rituximab 11Doxorubicin 10Prednisolone 9Etoposide 8Prednisone 7Thioguanine 6Teniposide 6Mitoxantrone 6Dasatinib 6venetoclax 5fludarabine phosphate 5Vindesine 5Stem Cell Transplantation 5Ifosfamide 5Azacitidine 4posaconazole 3pirtobrutinib 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 4 × Vitamin D × Other hematologic neoplasm × Clear all
NCT05340985 2022-04-22

Investigating the Effects of Hydroxyvitamin D3 on Multiple Sclerosis

Tehran University of Medical Sciences

Phase 4 Unknown
54 enrolled
LymphoidOther hematologic neoplasm

Multiple Sclerosis, Relapsing-Remitting, Precursor Cell Lymphoblastic Leukemia-Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡